“CLDX provided an encouraging overall pipeline outlook including a risk-mitigated CDX-011 registrational strategy, and favorable rindopepimut and CDX-1135 updates. We believe CLDX represents a compelling biotech play with 2 PIII and 3 PI/II candidates providing multiple shots on goal. Our new $15 PT assumes CLDX will develop/market CDX-011 on its own, booking all U.S. sales (v royalties from a partnership previously).,” the firm’s analyst wrote.
A number of other analysts have also recently weighed in on CLDX. Analysts at Roth Capital reiterated a buy rating on shares of Celldex Therapeutics in a research note to investors on Friday. They now have a $16.00 price target on the stock. Separately, analysts at Cantor Fitzgerald raised their price target on shares of Celldex Therapeutics from $13.00 to $16.00 in a research note to investors on Friday. They now have a buy rating on the stock. Finally, analysts at Leerink Swann initiated coverage on shares of Celldex Therapeutics in a research note to investors on Wednesday, March 6th. They set an outperform rating and a $18.00 price target on the stock.
Shares of Celldex Therapeutics traded up 0.46% during mid-day trading on Friday, hitting $11.945. Celldex Therapeutics has a one year low of $3.88 and a one year high of $12.49. The stock’s 50-day moving average is currently $8.66. The company’s market cap is $962.8 million.
Celldex Therapeutics, Inc. (Celldex) is a biopharmaceutical company, which applies its Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.